APA (7th ed.) Citation

Kater, A. P., Seymour, J. F., Hillmen, P., Eichhorst, B., Langerak, A. W., Owen, C., . . . Kipps, T. J. (2019). Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of clinical oncology, 37(4), 269-277. https://doi.org/10.1200/JCO.18.01580

Chicago Style (17th ed.) Citation

Kater, Arnon P., et al. "Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study." Journal of Clinical Oncology 37, no. 4 (2019): 269-277. https://doi.org/10.1200/JCO.18.01580.

MLA (9th ed.) Citation

Kater, Arnon P., et al. "Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study." Journal of Clinical Oncology, vol. 37, no. 4, 2019, pp. 269-277, https://doi.org/10.1200/JCO.18.01580.